Table SI. *Characteristics of 23 high-level resistant isolates of* P. acnes *from Denmark*

Isolate	Source	Phylo-type	Clonal cluster	ST	Mutation *23S rRNA*	*ErmX*	MIC ERY	MIC CLIND	Mutation *16S rRNA*	MIC TET	Treatment before sampling
R124.2	Acne	I-1a	CC3	3	2058A>G	-	>256	8	1058G>C +1202A>C	32	TET
R67.1	Acne	I-1a	CC3	3	2058A>G	-	>256	16	1058+1202	32	TET
R60.2	Acne	I-1a	CC3	3	2058A>G	-	>256	16	1058+1202	32	TET
R53.1	Acne	I-1a	CC3	3	*	-	>256	16	1058+1202	32	TET and local CLIND/BENZ
R52.2	Acne	I-1a	CC3	3	2058A>G	-	>256	16	1058+1202	32	ND
R50.1	Acne	I-1a	CC3	3	2058A>G	-	>256	8	1058+1202	32	Isotretinoin
R7.1	Acne	I-1a	CC3	3	2058A>G	-	>256	16	1058+1160C>T+1202	8	TET
R3.1	Acne	I-1a	CC3	3	2058A>G	-	>256	8	1058+1202	32	TET
15.2.A1	Acne	I-1a	CC3	3	2058A>G	-	>256	32	1058+1202	32	Local adapalene
29.1.L1	Acne	I-1a	CC3	3	2059A>G	-	1	8	1058+1202	32	
R114.2	Acne	I-1a	CC18	18	2059A>G	-	>256	1	-	8	TET and local CLIND/BENZ
R111.1	Acne	I-1a	CC18	18	-	+	>256	128	-	0.5	No treatment
R50.2	Acne	I-1a	CC18	18	2058A>G	-	>256	16	-	2	Isotretinoin
R3.2	Acne	I-1a	CC18	18	2059A>G	-	>256	4	-	4	TET
35.1.R1	Acne	I-1a	CC18	18	2059A>G	-	>256	16	-	2	No treatment
12.1.A12	Acne	I-1a	CC18	20	2059A>G	-	>256	4	-	1	Local acelaic acid
R33.4	Acne	I-1a	CC28	28	-	-	>256	1	-	2	TET and local CLIND
R5.1	Acne	I-1a	CC18	29	2057G>A	+	>256	128	1108G>A	0.25	Local CLIND/BENZ
15.2.L1	Acne	I-1a	CC18	29	2058A>G	-	>256	128	-	4	Local adapalene
R92.2	Acne	I-1b	CC31	30	-	+	>256	128	-	0.5	Local CLIND/BENZ
8.1.A1	Dermatologist	I-1b	CC31	31	2058A>G	-	>256	128	-	0.25	No treatment
16.2.A1	Acne	I-2	CC36	36	2058A>T	-	>256	8	-	2	Local BENZ
R113.1	Acne	II	CC53	52	2058A>C	-	>256	0.5	-	2	Local BENZ

*(R53.1 showed a mixture of A and G at position 2058 of the *23S rRNA* gene corresponding to alleles with and without the mutation and indicating heterogeneity among the 3 loci).

ST indicates multilocus sequence type and CC the clonal cluster; MIC ERY, MIC CLIND and MIC TET is the minimal inhibitory concentrations for erythromycin (ERY), clindamycin (CLIND) and tetracyclin (TET), respectively. Mutations in *23S* and *16S rRNA* are given as the position number in the corresponding *Escherichia coli rRNA* gene followed by the base change from wildtype base to (>) mutated base. Treatment in the months before sampling are given as TET (tetracyclin), CLIND (clindamycin) and BENZ (benzoylperoxide).